By Michael Dabaie


Incyte Corp. said Health Canada approved Minjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

The conditional approval is based on data from the L-MIND study and is supported by the RE-MIND study, an observational retrospective study in relapsed or refractory DLBCL. Removal of the conditions is contingent upon verification and description of clinical benefit in a confirmatory trial.

DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide, Incyte said, and is characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs.

Incyte and MorphoSys AG share global development rights to tafasitamab; Incyte has exclusive commercialization rights to tafasitamab outside the U.S. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S. and is marketed by Incyte under the brand name Minjuvi in Canada.


Write to Michael Dabaie at


(END) Dow Jones Newswires

August 24, 2021 09:14 ET (13:14 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Morphosys (XE:MOR)
Historical Stock Chart
Von Mai 2022 bis Jun 2022 Click Here for more Morphosys Charts.
Morphosys (XE:MOR)
Historical Stock Chart
Von Jun 2021 bis Jun 2022 Click Here for more Morphosys Charts.